ArticleCureus2026
Anticancer Potential of Thiocolchicoside: An In-Vitro MTT Assay Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thiocolchicoside (THC), a semi-synthetic derivative of colchicoside, is utilized clinically as a muscle relaxant. Nonetheless, its structural resemblance to colchicine indicates possible anticancer attributes. This study sought to assess the cytotoxic effects of THC on human mammary gland breast adenocarcinoma (MCF-7) and human gastric adenocarcinoma (AGS) cell lines utilizing the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, in comparison to VC. Cells were exposed to incremental dosages of THC 20-100 µg/ml and VC 20-100 µg/ml for 24 to 48 hours, and cell viability was evaluated. THC showed dose‑dependent cytotoxicity, reducing cell viability at higher concentrations, though less potent than VC. These results suggest that THC may have anticancer properties, necessitating more mechanistic and in vivo investigations. The aim was to study the anticancer effects of THC in various cell lines in comparison with the standard drug VC. The MCF-7 and AGS cell lines, which were chosen as exemplary models for the investigation, were procured from the National Centre of Cell Sciences (NCCS), Pune, India. Dimethyl Sulfoxide (DMSO), 200 µl, which was used as a control in this study, was procured from Thermo Fisher, Pune, India. THC was used as a test drug and was procured from Dr. Reddy's Laboratory Limited, Hyderabad, India, and VC, which was used as a reference drug, was procured from Yarrow Chem Products, Mumbai, India. The MTT reagent used in this study to monitor cell viability was procured from Thermo Fisher Scientific, Pune, India. Cell lines were treated with different concentrations of THC and VC ranging from 20 to 100 µg/ml for 24-48 hours, and absorbance was measured at 570 nm. After treatment, their cell viability was measured. VC exhibited markedly superior inhibitory action compared to THC in MCF-7 cells (p < 0.05); however, in AGS cells, the difference was not statistically significant (p > 0.05), suggesting comparable effects under the evaluated conditions. This shows THC has moderate cytotoxic activity. THC showed a dose-dependent decrease in cell viability and can be selected as a repurposing agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.